Cancer
In almost any organ, tumors can develop and the cancerous cells often spread within the body through the blood or the lymphatic system to form metastases. Among the most common cancers are:
- Prostate cancer
- Breast cancer
- Lung cancer
- Colon cancer
- Skin cancer (melanoma)
Tumor Antigens & Peptides
Tumor associated antigens are expressed by tumor cells and can be recognized by the host's immune system either by immune cells or by antibodies. Although tumor antigens are larger proteins, the detected T-cell epitopes are short peptides. In contrast, antibody epitopes can be linear, represented by relatively short peptide stretches, or they depend on a certain protein conformation that requires longer peptide sequences for proper interaction.
| Effector | Peptide Length | Presentation | Peptide Tool |
|---|---|---|---|
| CD8+ cytotoxic T cells | 8 - 10 aa | MHC I | Peptide Pools Peptide Libraries Antigen Peptides |
| CD4+ T cells | 12 - 18 aa | MHC II | Peptide Pools Peptide Libraries Antigen Peptides |
| Antibodies | small peptide epitopes | MHC independent | Peptide Microarrays Peptide ELISA |
Peptides as Radiosensitizers for Radiotherapy
Playing a key role in cancer treatment, radiotherapy is often challenged by intrinsic or aquired radioresistance in cancer cells. Radiosensitizing agents such as NF-kB inhibitors like SN50 and SN52 have shown promise by modulating vital cellular pathways related to survival, inflammation, and apoptosis. We at JPT offer a variety of peptide tools for radiotherapy research.
Chelate DOTA Peptides
Critical in medical applications, specifically cancer diagnosis and treatment, various chelating agents refered to as DOTA (tetraxetan) can bind to metallic cations. Such chelated metals then may act in peptide receptor radionuclide therapy, directing radiation in more targeted fashion to tumor cells.
Peptide Products & Services for Cancer Research
Sort by
JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.
JPT offers tailored custom peptides, peptide libraries and peptide pools for HCMV research. We provide knowledgeable support, high quality, flexible and innovative formats combined with expert know-how to bring forward your research project.
- Immune monitoring
- Immunotherapy
- Epitope discovery
- Ready-made peptide pools for TAAs such as Erb/Her2 and MAGE and for tumor viruses such as HPV
- Custom PepMix™ peptide pools
- Vaccine development
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
Individual peptides tailored to your needs. Flexible amount, purity, analysis and modification such phosphorylation, biotinlyation, fluorescence labels etc.
JPT is the technology leader for peptide microarrays. We offer a range of pre-made catalog peptide microarrays for multiple TAAs and production of customized peptide microarrays. In addition, we provide a modular assay and analysis service using high content peptide microarrays, multiwell microarrays and peptide ELISA.
- Immune monitoring of humoral response
- Profiling of cancer specific samples or antibodies
- Detection of epitopes and epitope spreading
- Vaccine target identification
- Catalog Peptide Microarray for TAAs such as Erb/Her2 and Survivin and for tumor viruses
- Tailored PepStar™ Peptide Microarrays: you define content and layout
In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental know-how for peptides. Peptide ELISA is offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
Histones
Histones are part of nucleosomes that build up the chromatin in eukaryotic cells. Histone proteins undergo a variety of post-translational modifications (PTMs e.g. methylation, acetylation, phosphorylation, citrullination). Combinations of these modifications regulate histone interaction with the DNA and other proteins, thus affecting diverse biological processes such as gene regulation, DNA repair, mitosis and meiosis. Abnormal histone modification patterns have been associated with a large number of human malignancies.
The Histone Code Peptide Microarray contains more than 3800 histone peptides with and without PTMs. All potential combinations of post-translational modifications are represented. JPT’s comprehensive Histone Code Microarray enables mapping of protein-histone interactions with unprecedented resolution.
Acetylation of lysine residues in proteins and peptides is a posttranslational modification (PTM) that plays a major role in regulating transcription and other metabolic processes. We created two high-density peptide microarrays, each displaying 5599 peptides derived from reported human non-histone acetylation targets.
Identification of biomarkers and profiling of protein expression signatures can be used to develop and improve anti-cancer therapies, diagnostics and to enhance our understanding of carcinogenesis and signaling pathways.
JPT produced sets of proteotypic peptides for the detection and relative quantification of the most relevant tumor associated antigens (TAA) and human cytokines using SRM/MRM assays.
The ready-to-use proteotypic peptide sets and pools are available in two specifications, containing either light or heavy isotope labeled peptides (C-terminal Arg U-13C6; U-15N4 or Lys U-13C6; U-15N2) and is delivered in three 96 well plates.
SpikeTides™ are tailored proteotypic peptides, delivered individually or pooled. The proteotypic peptides are synthesized with heavy isotope labeled or light arginine or lysine. For absolute quantification JPT developed a proprietary JPT-tag. The tagged proteotypic peptides enable a cost efficient and more reliable absolute quantification of peptide standards for proteome wide profiling using SRM/MRM proteomic assays.